New Issue | Current Pharmaceutical Design; Volume 25 Issue 17

 

Current Pharmaceutical Design publishes timely in-depth/mini reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

 

cpd-14-16.jpg

Articles from the journal: Current Pharmaceutical Design; Volume 25 Issue 17

 

For details on the articles, please visit this link:  http://www.eurekaselect.com/node/606/current-pharmaceutical-design/issue/25/2588/17/9258

Press Release | Dose-dependent effects of esmolol-epinephrine combination therapy in myocardial ischemia

 

The article by Dr. Tobias Eckle et al. is published in Current Pharmaceutical Design, Volume 25, 2019. The complete paper is published in Current Pharmaceutical Design. Please visit the following link to access the paper: http://www.eurekaselect.com/node/172732/article/dose-dependent-effects-of-esmolol-epinephrine-combination-therapy-in-myocardial-ischemia-and-reperfusion-injury

 

5d5d2c9903973.png

 

Epinephrine has been included in resuscitation guidelines worldwide since the 1960s. It is believed that epinephrine increases the chance of restoring a person’s heartbeat and improves long-term neurological outcome through increasing coronary and cerebral perfusion pressure. However, recent studies have raised doubts about the benefit of epinephrine regarding neurological outcomes in cardiac arrest. Moreover, epinephrine use in the stabilization of a cardiogenic shock in post-myocardial infarction patients has been found to increase the incidence of refractory shock. In fact, beta-adrenergic receptor stimulation has been suggested to have deleterious effects as stimulation of this pathway increases oxygen consumption and reduces sub-endocardial perfusion. In contrast, esmolol, a cardio-selective β1-blocker, has been shown to provide cardioprotection after myocardial ischemia in animal and human studies. Therefore, esmolol co-administration with epinephrine may help to reduce epinephrine-reperfusion injury but maintain esmolol-cardioprotection and epinephrine mediated increases in chronotropy and inotropy. Indeed, recent studies in animals have uncovered beneficial effects of epinephrine and esmolol co-administration in a cardiac arrest model. Based on these findings, Dr. Tobias Eckle and his team at the University of Colorado School of Medicine, University of Colorado have investigated esmolol-epinephrine combination therapy in a mouse model of myocardial ischemia and reperfusion injury.

Comparing different esmolol doses in combination with epinephrine in a mouse model of myocardial infarction, Eckle’s team demonstrated that at a specific esmolol-epinephrine ratio (15:1), esmolol-cardioprotection and epinephrine β1 mediated hemodynamic activity can both simultaneously exist during myocardial ischemia and reperfusion injury. “These findings might have implications for current clinical practice in the treatment of patients with cardiogenic shock or cardiac arrest”, says Eckle. “In fact, a cardiogenic shock after myocardial ischemia disallows the use of esmolol due to hemodynamic instability.” Interestingly, a definite recommendation for a specific catecholamine regimen in cardiogenic shock is lacking.

Combination therapy of epinephrine with esmolol seems less intuitive in cardiogenic shock after myocardial ischemia according to the research; higher esmolol doses could compromise epinephrine mediated increases of cardiac output via β1 adrenergic receptor inotropic and chronotropic effects, or higher epinephrine doses could compromise esmolol mediated cardioprotection via β1 adrenergic receptor blockade. Surprisingly, by increasing the esmolol dose, the study team was able to restore esmolol-cardioprotection while heart rate and some blood pressures in the early reperfusion phase were significantly increased compared to an esmolol treatment alone. “This finding is novel and highlights that esmolol cardioprotection is not fully understood,” says Eckle. Having increased heart rates, which is β1 mediated, and at the same time seeing cardioprotection via esmolol β1 blockade, indicates that only a part or short-term blockade of β1 receptors is necessary for the salutary effects of esmolol in myocardial ischemia and reperfusion injury.

While some clinicians occasionally use esmolol in patients on epinephrine infusion due to cardiogenic shock going off cardiac bypass to treat epinephrine-induced arrhythmias, no study to date has evaluated potential cardioprotective effects of esmolol-epinephrine co-administration during cardiac bypass surgery or a cardiogenic shock. As this is the first animal study on epinephrine-esmolol co-administration during myocardial ischemia and reperfusion injury, further studies in larger animals using multiple dosing protocols are suggested. Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-07/bsp-deo070219.php

Call for Papers | Current Pharmaceutical Design

Special Thematic Issues | Forthcoming Issues

Journal: Current Pharmaceutical Design

 

Guest Editor(s): Celestino Sardu
Tentative Publication Date: January, 2020

 

“Metabolic Syndrome impact on molecular, and cellular functions in patients affected by heart failure: therapeutic, diagnostic and clinical applications”

Ametabolic Syndrome.jpg

 

In this Special Issue we would try to bring the two major diseases together by focusing on common molecular pathways, mechanisms and subsequently on clinical outcomes. We may speculate that, the identification of mechanisms underlying the pathophysiology of MS and its CV complications may represent an area of significant research efforts, attracting scientists and clinicians from a diverse range of fields including biochemistry, pharmacology, internal medicine, cardiology and geriatrics among several others.Our Special Issue hypothesis is that, the final goal in the near future will be to find treatments better tailored to MS patients with HF using a personalized–medicine approach. Therefore, here we invite investigators to submit to this Special Issue both original research articles, clinical trials and reviews having the purpose to address novel diagnostic tools or new therapeutic treatments for MS and HF. For more details please visit: https://benthamscience.com/journal-files/special-issue-details/CPD-SII20181228-01.pdf

 

To submit your paper, email at: hermain@benthamscience.net and CC: faizan@benthamscience.net

Become a Reviewer | Current Pharmaceutical Design

 

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

The Journal Current Pharmaceutical Design is interested in appointing active Reviewer  on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Reviewer, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field, you can recommend suitable colleagues for the same, and, if possible, send their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at:

 

Wordpress - Reviewer.jpg

Become an Editorial Board Member (EBM) | Current Pharmaceutical Design

 

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

The Journal Current Pharmaceutical Design is interested in appointing active Editorial Board Member  on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Editorial Board Member, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field, you can recommend suitable colleagues for the same, and, if possible, send their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at:

 

Wordpress.jpg

Call for Papers | Current Pharmaceutical Design

Special Thematic Issues | Forthcoming Issues

Journal: Current Pharmaceutical Design

 

Guest Editor(s): Antoni Camins Espuny, Carlos Beas-zarate
Tentative Publication Date: November, 2019

“New Targets and strategies of Medical Treatments in neurological and neurodegenerative
disorders”

 

Current Pharmaceutical Design

 

The objective of this special issue is to give a vision of different pharmacological and nutritional strategies to develop new treatments for the prevention and cure of diseases that affect the central nervous system. Refractory epilepsy affects 20-30% of patients and constitutes a serious problem should be solved in the future knowing the cause of the loss of effectiveness of drugs. With reference to the other neurodegenerative diseases, it is evident that it is necessary to propose new strategies to solve the problem of cognitive loss in AD, for example, by stimulating the hippocampal insulin receptor, by inhibiting glial activity, or, by the development of new drug strategies through nanoparticles.

This thematic issue will gather information with and emphasis in new targets and strategies the potential therapeutic uses. Moreover, it will generate a forum for discussion of development of new pharmaceutical strategies (nanoparticles, etc) and effects, including the effect in different biological systems. For more details please visit: https://benthamscience.com/journal-files/special-issue-details/CPD-SII20190531-01.pdf

 

To submit your paper, email at: hermain@benthamscience.net and CC: faizan@benthamscience.net

 

Press Release | The circadian-hypoxia link in cardioprotection

 

This article by Dr. Tobias Eckle and Dr. Colleen Marie Bartman is published in Current Pharmaceutical Design, 2019. For further details, please visit: http://www.eurekaselect.com/172148

 

203252_web.jpg

 

Circadian rhythms are 24 hour cycles that are guided by exposure to alternating periods of day and night. These cycles affect biological activities in a variety of living organisms which are attuned to the circadian clock. A disturbance in circadian patterns is known to affect many biomolecular processes linked with metabolism and other physiological functions. Dr. Tobias Eckle and his team at the University of Colorado Anschutz Medical Campus have studied circadian rhythms in detail. Eckle’s recent research has specifically been directed towards identifying cellular adaptive mechanisms during hypoxic conditions such as myocardial ischemia – one of the leading causes of morbidity and mortality worldwide. The team has published their review in Current Pharmaceutical Design.

Adenosine signaling has been implicated in cardiac adaptation to limited oxygen availability. In a wide search for adenosine receptor elicited cardio-adaptive responses, Eckle’s group identified the circadian rhythm protein period 2 (PER2) as an adenosine signaling target. The researchers found that PER2 KO mice had larger infarct sizes and a limited ability to use carbohydrates for oxygen-efficient glycolysis compared to wild-type mice. This impairment was caused by a failure to stabilize the oxygen sensor hypoxia-inducible factor-1 alpha (HIF1A). Moreover, stabilization of PER2 in the heart by exposing mice to intense light resulted in the transcriptional induction of HIF1A regulated glycolytic enzymes and PER2-dependent cardio-protection from ischemia. Ongoing studies are attempting to elucidate the role of the light regulated circadian rhythm protein PER2 as an oxygen and metabolic sensor during conditions of limited oxygen availability.

In their comprehensive review article, Eckle et al. discuss an evolutionary link between light and oxygen sensing pathways in depth and provide an insight into molecular and cellular adaptation for resilience to adverse changes in the environment:

The appearance of sunlight and oxygen on earth were undoubtedly the most dramatic environmental changes during evolution. As a result, almost all organisms on this planet are equipped with light and oxygen sensing pathways. Notably, light sensing and oxygen sensing pathways in mammals are linked on a cellular level: Hypoxia inducible factor 1? (HIF1A), an evolutionarily conserved transcription factor enabling cellular adaptation to low oxygen availability, belongs to the same protein family as the light-regulated circadian core protein Period 2 (PER2). Both belong to the PAS domain superfamily of signal sensors for oxygen, light, or metabolism. As such, Hif1? messenger RNA levels cycle in a circadian manner in mouse cardiac tissue and rhythmic oxygen levels reset the circadian clock through HIF1A. “This evolutionary conserved relationship between light (circadian) and oxygen sensing pathways suggests a role for light elicited circadian rhythm proteins in disease states of low oxygen availability, such as myocardial ischemia,” states Eckle. He concludes that “Insights gained from an advanced understanding of this evolutionarily conserved relationship between light and oxygen sensing pathways, will ultimately provide new therapeutic opportunities to treat such diseases.” Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-06/bsp-tcl061119.php

 

New Issue | Current Pharmaceutical Design (Volume: 25, Issue: 3)

 

Current Pharmaceutical Design publishes timely in-depth/mini reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

 

cpd-14-16.jpg

 

Articles from the journal: Current Pharmaceutical Design; Volume: 25, Issue: 3

 

 

For details on the articles, please visit this link: http://www.eurekaselect.com/node/606/current-pharmaceutical-design/issue/25/2588/3/9101

Become an Editorial Board Member (EBM) | Current Pharmaceutical Design

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

The Journal Current Pharmaceutical Design is interested in appointing active Editorial Board Member  on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Editorial Board Member, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field, you can recommend suitable colleagues for the same, and, if possible, send their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at:

 

Wordpress.jpg

Become a Reviewer | Current Pharmaceutical Design

 

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

The Journal Current Pharmaceutical Design is interested in appointing active Reviewer  on the Journal’s Board. If you are working in the related field as of the journal and are interested in becoming an Reviewer, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field, you can recommend suitable colleagues for the same, and, if possible, send their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at:

 

Wordpress - Reviewer.jpg

%d bloggers like this: